Alvogen launches first generic equivalent of Copaxone in Europe

First Generic and clinically validated product for Multiple Sclerosis in Europe.

The product will be launched with a proprietary auto-injector device (Autoxon) having multiple features to help support MS patients in their treatment with Remurel. Teva‘s Copaxone delivered sales of over EUR 510 million in Europe in 2015, according to IMS Midas data.

Hacho Hatchikian, Executive Vice President at Alvogen in the CEE region, commented: "We are proud to announce the launch of Remurel. This product represents an important milestone in our growing portfolio in the region. It is also a landmark for Alvogen and MS patients throughout the CEE region, who will finally have access to an affordable high quality treatment for this chronic and neurodegenerative disease. This is yet another first-to-market complex product in our portfolio, testifying to Alvogen’s commitment in delivering difficult-to-make but affordable treatments to patients. Remurel offers a more affordable – but equally effective - treatment option for Multiple Sclerosis patients, offering compelling cost saving opportunities within the Central and Eastern European region."